MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immune-based Therapies

The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

Cancer Chemotherapy and Pharmacology 2017 November 10 [Epub ahead of print] [Link] Matherly LH, Hou Z, Gangjee A Abstract This review considers the “promise” of exploiting the proton-coupled folate transporter (PCFT) for selective therapeutic targeting of cancer. PCFT was discovered in 2006 and was identified as the principal folate transporter involved in the intestinal absorption […]

Comments Off on The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma

Molecular Oncology 2017 November 1 [Epub ahead of print] [Link] Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF […]

Comments Off on A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma

Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining

Cancer. 2017 September 18 [Epub ahead of print] [Link] Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A Abstract BACKGROUND: Malignant mesothelioma (MM) is an aggressive, fatal tumor. Current therapeutic options only marginally improve survival. Programmed cell death ligand 1 (PD-L1) is a dominant mediator of immunosuppression, binding to programmed cell death […]

Comments Off on Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining

The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients

Cancer Immunology, immunotherapy [Epub 2017 March 13] [Link] Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U Abstract Malignant pleural effusions are frequent in patients with advanced stages of lung cancer and are commonly infiltrated by lymphocytes and tumor cells. CD8+ T cells from these effusions have reduced effector functions. The programmed death receptor 1(PD-1)/programmed death […]

Comments Off on The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients

Oncolytic Viral Therapy for Mesothelioma

Frontiers in Oncology 2017 August 24 [Link] Pease DF, Kratzke RA Abstract The limited effectiveness of conventional therapy for malignant pleural mesothelioma demands innovative approaches to this difficult disease. Even with aggressive multimodality treatment of surgery, radiation, and/or chemotherapy, the median survival is only 1-2 years depending on stage and histology. Oncolytic viral therapy has emerged […]

Comments Off on Oncolytic Viral Therapy for Mesothelioma

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Cancers 2017 September [Link] Klampatsa A, Haas AR, Moon EK, Albelda SM Abstract Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs […]

Comments Off on Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)

Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Human Pathology 2017 August 12 [Epub ahead of print] [Link] Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M Abstract Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. […]

Comments Off on Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma

Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Cytokine & Growth Factor Reviews 2017 July 12 [Epub ahead of print] [Link] Calabrò L, Ceresoli GL, D’Incecco A, Scherpereel A, Aerts J, Maio M Abstract Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), […]

Comments Off on Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

The Lancet.Oncology 2017 July 17 [Epub ahead of print] [Link] Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL Abstract BACKGROUND: New therapeutic strategies for malignant mesothelioma are […]

Comments Off on Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Novel systemic therapy against malignant pleural mesothelioma

Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum […]

Comments Off on Novel systemic therapy against malignant pleural mesothelioma